Livzon Group’s anti-FXI bispecific antibody approved for clinical trials
Valid market news retained in the public archive without immediate LiveCast distribution.
Related stories
KBR Reports Quarterly Results for Period Ended September 30
KBR reported results for the quarter ended September 30; no figures were provided.
M impact | EQUITY | Oct 29, 2026, 01:34 PM UTC
Alphabet Shares Fall 12%
M impact | EQUITY | Oct 29, 2026, 01:34 PM UTC
Entegris Reports Q3 Revenue of $1.005 Billion, Issues Q4 Outlook
Third-quarter revenue rose 24.5% year over year to $1.005 billion. GAAP earnings were $157.8 million, or $1.03 per share; adjusted earnings were $189.7 million, or $1.23 per share.
M impact | EQUITY | Oct 29, 2026, 01:34 PM UTC
Leonardo DRS Q3 Revenue Rises 11%; Raises 2026 Guidance
Revenue was $1.1 billion and net earnings rose 60% to $115 million. Adjusted diluted EPS increased 59% to $0.46; bookings were $1.6 billion, with a 1.5x book-to-bill ratio and reco
M impact | EQUITY | Oct 29, 2026, 01:34 PM UTC
Harley-Davidson Reports Q3 Results, Raises 2026 Guidance
Harley-Davidson reported Q3 2026 results, including a 9% year-over-year increase in North American retail sales of new motorcycles. It raised full-year guidance for both HDMC and H
M impact | EQUITY | Oct 29, 2026, 01:34 PM UTC
Teck Resources reports quarterly results for period ended September 30
M impact | EQUITY | Oct 29, 2026, 01:34 PM UTC